The success of outsourcing bioprocesses often hinges on managing interpersonal dynamics and team collaboration, which are frequently underestimated compared to technical challenges. The human element, including politics between companies, is a major pitfall where tech transfer projects struggle.
Instead of accepting inconsistent results, proactively address the root causes. Variability is a problem that can be solved through better raw material selection, improved process design, or increased lab automation, leading to more reproducible and reliable outcomes.
Instead of a jarring switch, gradually integrate GMP-like practices into daily operations, such as structured documentation and a quality-focused culture. This proactive approach smooths the eventual transition into a regulated framework without 'overkilling it' with excessive early investment.
Lab-scale processes often contain methods, like certain purifications, that are not commercially scalable. It is critical to identify and redevelop these elements early to avoid hitting a manufacturing wall, even if it introduces temporary changes to the product profile.